retatrutide weight loss retatrutide clinical trial Results:Trial Data and FDA Status Retatrutide (“reta”) is an experimental

Mitochondrial biogenesis transcripts (PGC-1 targets), fatty acid oxidation genes, and DDIT4 an acute aerobic exercise gene were upregulated within hours of a single IP dose (Billon et al., ACS Chem Biol 2023, PMID 36988910)

Despite the improvement in GH/IGF-1 levels (GH 10.6 ng/mL, IGF-1 462 ng/mL), her glycemic control drastically deteriorated for 4 months (Hb1Ac 8.212.0%)

And move on without guilt

GLP-1 medications may increase skin reactivity slightly, especially in patients who experience the skin barrier impairment that some research has documented

Taking Ozempic for weight loss is considered off-label even for those who are obese

Report all suspected adverse reactions to your trial team and to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)